CN1546474A - 四甲基吡嗪生产方法 - Google Patents
四甲基吡嗪生产方法 Download PDFInfo
- Publication number
- CN1546474A CN1546474A CNA2003101023680A CN200310102368A CN1546474A CN 1546474 A CN1546474 A CN 1546474A CN A2003101023680 A CNA2003101023680 A CN A2003101023680A CN 200310102368 A CN200310102368 A CN 200310102368A CN 1546474 A CN1546474 A CN 1546474A
- Authority
- CN
- China
- Prior art keywords
- tetramethylpyrazine
- butanone
- phosphoric acid
- amino
- ligustrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 title claims abstract description 216
- 238000000034 method Methods 0.000 title claims abstract description 62
- QCWWEZIJUCPALZ-UHFFFAOYSA-N 1-aminobutan-2-one Chemical compound CCC(=O)CN QCWWEZIJUCPALZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 230000008569 process Effects 0.000 claims abstract description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 104
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 18
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- 239000013078 crystal Substances 0.000 claims description 12
- MAAZDFZETNADTQ-UHFFFAOYSA-N 2,3,5,6-tetramethylpyrazine;trihydrate Chemical compound O.O.O.CC1=NC(C)=C(C)N=C1C MAAZDFZETNADTQ-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- CYKLCZRAQAFYDC-UHFFFAOYSA-N 1,2,2,3-tetramethylpyrazine Chemical compound CN1C=CN=C(C)C1(C)C CYKLCZRAQAFYDC-UHFFFAOYSA-N 0.000 claims description 9
- 238000009833 condensation Methods 0.000 claims description 8
- 230000005494 condensation Effects 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 6
- 238000005839 oxidative dehydrogenation reaction Methods 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 150000004684 trihydrates Chemical class 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 36
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 30
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 229910052801 chlorine Inorganic materials 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000006482 condensation reaction Methods 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- AALRHBLMAVGWRR-UHFFFAOYSA-N 1-chlorobutan-2-one Chemical group CCC(=O)CCl AALRHBLMAVGWRR-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 235000011114 ammonium hydroxide Nutrition 0.000 description 9
- 235000011121 sodium hydroxide Nutrition 0.000 description 9
- 125000002587 enol group Chemical group 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000007670 refining Methods 0.000 description 6
- 238000004176 ammonification Methods 0.000 description 5
- 238000005660 chlorination reaction Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 150000004715 keto acids Chemical class 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 229920001084 poly(chloroprene) Polymers 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- -1 [O] Chemical compound 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 2
- 238000007171 acid catalysis Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- OLYWGXUJESDUAC-UHFFFAOYSA-N 3-aminobutan-2-one Chemical compound CC(N)C(C)=O OLYWGXUJESDUAC-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- FSEUPUDHEBLWJY-HWKANZROSA-N diacetylmonoxime Chemical compound CC(=O)C(\C)=N\O FSEUPUDHEBLWJY-HWKANZROSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- AWYNTSYRHFZMKN-UHFFFAOYSA-N ethanol 2,3,5,6-tetramethylpyrazine Chemical compound C(C)O.CC1=C(N=C(C(=N1)C)C)C AWYNTSYRHFZMKN-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- RQKFOGXUTRDQPB-UHFFFAOYSA-N hydron;2,3,5,6-tetramethylpyrazine;chloride Chemical compound Cl.CC1=NC(C)=C(C)N=C1C RQKFOGXUTRDQPB-UHFFFAOYSA-N 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- KWWLGXNRLABSMP-UHFFFAOYSA-N phosphoric acid;2,3,5,6-tetramethylpyrazine Chemical compound OP(O)(O)=O.CC1=NC(C)=C(C)N=C1C KWWLGXNRLABSMP-UHFFFAOYSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310102368 CN1238344C (zh) | 2003-10-27 | 2003-10-27 | 四甲基吡嗪生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310102368 CN1238344C (zh) | 2003-10-27 | 2003-10-27 | 四甲基吡嗪生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1546474A true CN1546474A (zh) | 2004-11-17 |
CN1238344C CN1238344C (zh) | 2006-01-25 |
Family
ID=34333172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310102368 Expired - Lifetime CN1238344C (zh) | 2003-10-27 | 2003-10-27 | 四甲基吡嗪生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1238344C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100556895C (zh) * | 2006-10-18 | 2009-11-04 | 张锋 | 川芎嗪的制备方法 |
CN103664803A (zh) * | 2012-09-17 | 2014-03-26 | 王天桃 | 2,3,5,6-四甲基吡嗪新的合成方法 |
CN107556251A (zh) * | 2017-08-23 | 2018-01-09 | 广东昊邦医药健康有限责任公司 | 一种磷酸川芎嗪衍生化合物及其药物组合物 |
CN108892645A (zh) * | 2018-09-15 | 2018-11-27 | 广州方中化工有限公司 | 一种制备四甲基吡嗪的方法 |
-
2003
- 2003-10-27 CN CN 200310102368 patent/CN1238344C/zh not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100556895C (zh) * | 2006-10-18 | 2009-11-04 | 张锋 | 川芎嗪的制备方法 |
CN103664803A (zh) * | 2012-09-17 | 2014-03-26 | 王天桃 | 2,3,5,6-四甲基吡嗪新的合成方法 |
CN107556251A (zh) * | 2017-08-23 | 2018-01-09 | 广东昊邦医药健康有限责任公司 | 一种磷酸川芎嗪衍生化合物及其药物组合物 |
CN108892645A (zh) * | 2018-09-15 | 2018-11-27 | 广州方中化工有限公司 | 一种制备四甲基吡嗪的方法 |
CN108892645B (zh) * | 2018-09-15 | 2021-07-13 | 广州方中化工有限公司 | 一种制备四甲基吡嗪的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1238344C (zh) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103694175A (zh) | 一种制备盐酸右美托咪定的新方法 | |
CN103626775B (zh) | 具有二嗪结构的dpp-4抑制剂 | |
CN1238344C (zh) | 四甲基吡嗪生产方法 | |
CN105085373A (zh) | 一种对阿普斯特产品的纯化方法 | |
CN101054346A (zh) | 一组新化合物及其组合物的制备方法和用途 | |
CN102367236A (zh) | 一种盐酸多奈哌齐的合成工艺 | |
CN104031105A (zh) | 一种胞磷胆碱钠的制备方法 | |
CN1075072C (zh) | 噁唑烷酮衍生物及其制法和用途 | |
CN1443178A (zh) | (r)-n-[5-甲基-8-(4-甲基哌嗪-1-基)-1,2,3,4-四氢-2-萘基]-4-吗啉代苯甲酰胺的新形态 | |
CN102558133A (zh) | 一种3-(3’,4’-次甲二氧苯基)-丙烯酰哌啶的工业化合成工艺 | |
CN102417472A (zh) | 一种氟苯尼考的制备方法 | |
CN105646324A (zh) | 一种高纯度吲哚的制备方法 | |
CN1064809A (zh) | 药剂 | |
CN1743321A (zh) | 一种含有苯丙烯叉基噻唑烷乙酸的制备方法 | |
JP2003064081A (ja) | 新規なオクタヒドロ−2H−ピリド〔1,2−a〕ピラジン化合物、それらの製造方法およびそれらを含む医薬組成物 | |
CN103193699B (zh) | 一种制备普卡必利中间体的新方法 | |
CN102250013A (zh) | 阿苯达唑的制备方法 | |
CN107011228B (zh) | 一种富马酸氯马斯汀的制备方法 | |
CN102827174A (zh) | 一种醛糖还原酶抑制剂非达司他的制备方法 | |
EP2723719B1 (fr) | Dérivés de pipérazine, leurs procédés de préparation et leurs utilisations dans le traitement de l'insulinorésistance | |
CN103193712B (zh) | 一种l-肌肽的制备方法 | |
CN1711233A (zh) | 制备茚满-1,3-二甲酸的方法 | |
CN107686439A (zh) | 一种alk抑制剂的关键中间体的制备方法 | |
JP2019524811A (ja) | ヒドロニドンの製造方法 | |
CN105153050A (zh) | 一种喹烯酮衍生物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Livzon Syntpharm Co.,Ltd. (Zhuhai FTZ) Assignor: LI MIN PHARMACEUTICAL FACTORY OF LIVZON PHARMACEUTICAL Group Contract fulfillment period: 2008.7.31 to 2018.7.31 Contract record no.: 2008990000338 Denomination of invention: Method for preparing tetramethyl pyrazine Granted publication date: 20060125 License type: Exclusive license Record date: 20080826 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.7.31 TO 2018.7.31 Name of requester: LIZHU SYNTHESIS PHARMACY CO., LTD., ZHUHAI BONDED Effective date: 20080826 |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060125 |